Our research group specializes in the study of the pathophysiological processes of cardiovascular diseases, particularly dilated cardiomyopathy and atherosclerosis. We are a translational research group composed of clinical and basic researchers. Currently, our research focuses on developing a tool based on the molecular signature of non-coding RNAs in combination with clinical and echocardiographic variables, which will enable the early identification of patients with dilated cardiomyopathy—the most common cause of heart failure, with a prevalence of 1 in 250. Furthermore, we address the clinical need to identify patients with statin intolerance who are at high vascular risk. The primary objective of this line of research is to characterize the molecular mechanisms involved in the muscle damage that occurs in these patients, thereby identifying new therapeutic alternatives to lower elevated cholesterol levels. For both lines of research, we combine research strategies using cellular models (cardiomyocytes, muscle cells), patient studies (involving patients with dilated cardiomyopathy of various etiologies, statin intolerance, and high cardiovascular risk), and the development of ex vivo assays using samples obtained from these patients.